Reuters exclusively reported that Only about one-third of patients prescribed a popular weight-loss drug like Novo Nordisk’s (NOVOb.CO) Wegovy were still taking it a year later, while total healthcare costs for the group rose sharply.
Most patients using weight-loss drugs like Wegovy stop within a year, data show
11 July 2023, 5:39 pm 1 minute
Shares of the Danish drugmaker fell 2.3% on Tuesday.
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Countries: United States
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Significant National Story
More of Reuters Best
September 04, 2023
August 28, 2023